G1 Therapeutics, Inc. - Common Stock (NQ:GTHX)

7.150 UNCHANGED

Last Price Updated: 4:00 PM EDT, Sep 17, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about G1 Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer

September 18, 2024

From G1 Therapeutics

Via GlobeNewswire

Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period

September 05, 2024

From G1 Therapeutics

Via GlobeNewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GVP, PETQ, GTHX on Behalf of Shareholders

August 15, 2024

From Halper Sadeh LLC

Via GlobeNewswire

Why Is G1 Therapeutics (GTHX) Stock Up 66% Today? ↗

August 07, 2024

G1 Therapeutics stock is up on Wednesday following news that Pharmacosmos Group is acquiring GTHX for $7.15 per share.

Via InvestorPlace

Analyst Ratings For G1 Therapeutics ↗

June 13, 2024

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Thoughtworks Holding, Inc. (Nasdaq – TWKS), PetIQ, Inc. (Nasdaq – PETQ), G1 Therapeutics, Inc. (Nasdaq – GTHX), GSE Solutions, Inc. (Nasdaq – GVP)

August 15, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

G1 THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of G1 Therapeutics, Inc. - GTHX

August 09, 2024

From Kahn Swick & Foti, LLC

Via Business Wire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GTHX, PETQ on Behalf of Shareholders

August 09, 2024

From Halper Sadeh LLC

Via GlobeNewswire

August 08, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights

August 08, 2024

From G1 Therapeutics

Via GlobeNewswire

Dow Tumbles Over 200 Points; CVS Health Cuts Profit Forecast ↗

August 07, 2024

Via Benzinga

Topics Stocks

Crude Oil Jumps Over 3%; Upstart Shares Spike Higher ↗

August 07, 2024

Via Benzinga

Nasdaq Jumps 250 Points; Disney Earnings Beat Estimates ↗

August 07, 2024

Via Benzinga

Topics Earnings

GTHX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of G1 Therapeutics, Inc. Is Fair to Shareholders

August 07, 2024

From Halper Sadeh LLC

Via Business Wire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

August 07, 2024

Pre-market stock movers are a hot topic on Wednesday and we have all of the latest news traders need to know about them this morning!

Via InvestorPlace

Pharmacosmos Group to Acquire G1 Therapeutics

August 07, 2024

From G1 Therapeutics; Pharmacosmos

Via GlobeNewswire

G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

July 25, 2024

From G1 Therapeutics

Via GlobeNewswire

G1 Therapeutics Stock: The Undervalued Gem Poised for a 30% Revenue Surge by 2025 ↗

July 15, 2024

While there’s no denying that G1 Therapeutics stock is highly speculative, investors should still check under the hood.

Via InvestorPlace

Biotech Bombshell: G1 Therapeutics Stock Is Too Much of a Gamble ↗

July 10, 2024

G1 Therapeutics stock is highly volatile, and investors should be wary now as G1 Therapeutics recently failed to achieve a clinical goal.

Via InvestorPlace

Ball To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

June 25, 2024

Via Benzinga

Coffee Recall 2024: Over 250 Coffee Products Recalled Due to Botulism Fears ↗

June 24, 2024

A 2024 coffee recall is in effect for products made by Snapchill LLC due to concerns of botulism from the FDA for hundreds of canned coffees.

Via InvestorPlace

Ginkgo Bioworks Layoffs 2024: What to Know About the Latest DNA Job Cuts ↗

June 24, 2024

Ginkgo Bioworks layoffs are a hot topic as the company prepares to cut 158 jobs this week with more headcount reductions coming next week.

Via InvestorPlace

Topics Workforce

Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares Surge ↗

June 24, 2024

Alnylam Pharmaceuticals reports positive results from the HELIOS-B Phase 3 study of vutrisiran for ATTR amyloidosis with cardiomyopathy. The trial showed significant reductions in mortality and...

Via Benzinga

Why Is Cancer-Focused G1 Therapeutics Stock Trading Lower On Monday? ↗

June 24, 2024

Shares of G1 Therapeutics are down after release of Phase 3 trial results for trilaciclib in TNBC.

Via Benzinga

Why Is G1 Therapeutics (GTHX) Stock Down 56% Today? ↗

June 24, 2024

G1 Therapeutics stock is down on Monday as GTHX investors react to the company's Phase 3 clinical trial of trilaciclib failing.

Via InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

June 24, 2024

It's time to dive into the biggest pre-market stock movers as we check out all of the hottest news on Monday morning!

Via InvestorPlace

G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)

June 24, 2024

From G1 Therapeutics

Via GlobeNewswire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

June 11, 2024

Via Benzinga

Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

May 28, 2024

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

May 28, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.